New Sugar-Based scan could predict brain tumor treatment response
NCT ID NCT06855628
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This study tests whether a new type of imaging called Deuterium Metabolic Imaging (DMI) can predict how well glioblastoma patients respond to treatment. Ten participants will drink a special sugar solution before scans to see how their tumors process glucose. The goal is to find a better way to tell early on if a treatment is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Palo Alto, California, 94305, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Deuterated glucose tracer (a special sugar drink used for imaging)
What this could lead to
If successful, this imaging technique could help doctors predict which glioblastoma patients will respond to a specific treatment, leading to more personalized care.
What could go wrong
This is a very small, early-phase study (only 10 participants) that is currently suspended. The imaging method is experimental and may not prove useful in predicting outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.